— Vertex Pharmaceuticals (NASDAQ: VRTX) reported third-quarter 2019 earnings of $1.23 per share, vs. $1.15 per share expected
— Total revenue grew 21% to $949.8 million, vs $950.9 million expected.
— Reiterated FY19 product revenues guidance of $3.70 – 3.75 billion. Non-GAAP effective tax rate outlook was also unchanged at 21-22%.
— VRTX shares were down 0.14% immediately following the announcement.
Most Popular
FAST Stock: Fastenal’s long-term prospects intact. Should you invest now?
Production disruption and logistics issues continue to have a crippling effect on the industrial sector but the performance of companies, in general, has been mixed so far. Fastenal Company (NASDAQ:
Netflix (NFLX) adds 8.3 million new subscribers in Q4: earnings beat estimates
Netflix, Inc. (NASDAQ: NFLX) Thursday said it added 8.3 million paid members in the December quarter. Revenues increased and matched estimates, aided by the relaxation of COVID restrictions and resumption
SCHW Stock: Upbeat stock market, rate hikes to drive growth for Charles Schwab
Investment management firm Charles Schwab Corporation (NYSE: SCHW) has stayed largely unaffected by the coronavirus crisis, rather it managed to tap into new opportunities. The company owes its impressive financial
